Preventing Opioid Abuse: Impact of Tamper-Resistant Formulations

The study was supported by untied educational grants from Mundipharma; research fellowships from the National Health and Medical Research Council (NHMRC); and the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund.

Several investigators report receiving untied educational grants from Reckitt Benckiser.

TRENDING ON CPA: Equalizing The Pain Pendulum 

Mundipharma and Reckitt Benckiser are both makers of abuse-deterrent opioid formulations.


1.      OxyContin tamper-resistant oxycodone tablets. Drugs and Poisons Regulation, April 2015. From the department of health and human services, state government of Victoria, Australia. Available at:,d.cGc. Accessed: October 20, 2015

2.      Degenhardt L, Bruno R, Ali R, Lintzeris N, Farrell M, Larance, B. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug and Alcohol Dependence. 2015; 151: 56-67. doi:10.1016/j.drugalcdep.2015.02.038

3.      Larance B, Lintzeris N, Bruno R et al. The characteristics of a cohort who tamper with prescribed and diverted opioid medications. Journal of Substance Abuse. 2015; 58: 51-61. doi:10.1016/j.jsat.2015.06.001